Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis

SWALES, John G., TUCKER, James W., STRITTMATTER, Nicole, NILSSON, Anna, COBICE, Diego, CLENCH, Malcolm, MACKAY, C. Logan, ANDREN, Per E., TAKÁTS, Zoltán, WEBBORN, Peter J. H. and GOODWIN, Richard J. A. (2014). Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis. Analytical chemistry, 86 (16), 8473-8480.

Preview	PDF Clench_MSI_Cassette_Dosing_Final_(3).pdf - Accepted Version Download (1MB) | Preview
Preview	PDF Clench_MSI_Cassette_Dosing_Supporting_Information.pdf - Accepted Version Download (241kB) | Preview

Abstract

Cassette dosing of compounds for preclinical drug plasma pharmacokinetic analysis has been shown to be a powerful strategy within the pharmaceutical industry for increasing throughput while decreasing the number of animals used. Presented here for the first time is data on the application of a cassette dosing strategy for label-free tissue distribution studies. The aim of the study was to image the spatial distribution of eight nonproprietary drugs (haloperidol, bufuralol, midazolam, clozapine, terfenadine, erlotinib, olanzapine, and moxifloxacin) in multiple tissues after oral and intravenous cassette dosing (four compounds per dose route). An array of mass spectrometry imaging technologies, including matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI MSI), liquid extraction surface analysis tandem mass spectrometry (LESA-MS/MS), and desorption electrospray ionization mass spectrometry (DESI-MS) was used. Tissue analysis following intravenous and oral administration of discretely and cassette-dosed compounds demonstrated similar relative abundances across a range of tissues indicating that a cassette dosing approach was applicable. MALDI MSI was unsuccessful in detecting all of the target compounds; therefore, DESI MSI, a complementary mass spectrometry imaging technique, was used to detect additional target compounds. In addition, by adapting technology used for tissue profiling (LESA-MS/MS) low spatial resolution mass spectrometry imaging (∼1 mm) was possible for all targets across all tissues. This study exemplifies the power of multiplatform MSI analysis within a pharmaceutical research and development (R&D) environment. Furthermore, we have illustrated that the cassette dosing approach can be readily applied to provide combined, label-free pharmacokinetic and drug distribution data at an early stage of the drug discovery/development process while minimizing animal usage.

Item Type:	Article
Research Institute, Centre or Group - Does NOT include content added after October 2018:	Biomedical Research Centre
Identification Number:	https://doi.org/10.1021/ac502217r
Page Range:	8473-8480
Depositing User:	Hilary Ridgway
Date Deposited:	30 Sep 2014 08:48
Last Modified:	18 Mar 2021 08:01
URI:	https://shura.shu.ac.uk/id/eprint/8495

Actions (login required)

View Item

Downloads

Publication Metrics